NanoKTN Announces Start of UK NanoRegen Mission to Germany and Austria
News Sep 06, 2012
The Nanotechnology Knowledge Transfer Network has announced the start of the NanoRegen Mission 2012, which is taking a delegation of six UK companies and academics specialised in developing materials for use in tissue engineering and regenerative medicine to Austria and Germany. The mission, organised in partnership with the Science and Innovation Network, Berlin and Chemistry Innovation KTN, aims to raise the profiles of UK companies abroad and help foster links with overseas suppliers and potential customers, ensuring the future of UK nanotechnology is embedded in the global market.
The UK, Germany and Austria all have significant expertise within the multidisciplinary field of regenerative medicine, but to ensure further product development and commercialisation, the convergence and co-operation of companies and academics alike is required. The mission provides an opportunity for UK companies and academic institutions to engage with key personnel and groups from Germany and Austria, with the aim of finding collaborators with whom new ideas can be formed and thus challenges solved.
The Mission is being led by Professor Chris Mason, Head of the Regenerative Medicine Bioprocess Group in the Advanced Centre for Biochemical Engineering at UCL, who will be joined by a UK delegation comprising of The Electrospinning Company, Giltech Ltd, Neotherix, Orla Protein Technologies Ltd, Pharmidex and University of Oxford. Each delegate will be given the opportunity to speak at the workshops arranged at the Fraunhofer IZI, Leipzig and the British Embassy, Berlin. The NanoRegen Mission will conclude with attendance at the 3rd TERMIS World Congress.
“International missions are hugely valuable to UK SMEs and academics. At the NanoKTN we support the exploitation and commercialisation of nanotechnologies and the aim of this mission is to help UK SMEs explore what is available in Germany and Austria. The four day mission will provide a major networking opportunity and platform for the UK delegation to present its work and we are sure it will see the same success we have seen with past missions,” says Dr Alec Reader, Director at the NanoKTN.
A human pluripotent stem cell line has been engineered which contains two ‘suicide genes’ that induce cell death in all but the desired insulin-producing cells. This double fail-safe approach opens the door to creating safe cell-replacement therapies for people living with type 1 diabetes.READ MORE